A Prospective Study of Early Tapering of Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after High Risk Allogeneic Hematopoietic Stem Cell Transplantation

A Prospective Study of Early Tapering of Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after High Risk Allogeneic Hematopoietic Stem Cell Transplantation - MMF Early Taper Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016523

Enrollment

Registered

2015-04-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute leukemia, MDS

Interventions

MMF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: high risk AML,ALL,MDS allo-HSCT

Exclusion criteria

Exclusion criteria: CBT

Design outcomes

Primary

Measure	Time frame
1year OS	—

Countries

Japan

Contacts

Public ContactKeiji Kurata

Kobe University Hospital Oncology/Hematology

kkurata@med.kobe-u.ac.jp+81-78-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026